SCHEMBL14235384

SCHEMBL14235384

CNc1ccc2c(n1)NC(=O)C(C)(C)O2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 4/20 0.49
▸ ADORA3 P0DMS8 2/20 0.45
▸ TYRO3 Q06418 2/20 0.45
▸ NTRK1 P04629 2/20 0.45
▸ NTRK3 Q16288 2/20 0.45
▸ NTRK2 Q16620 2/20 0.45
▸ BMPR1B O00238 1/20 0.45
▸ CDC7 O00311 1/20 0.45
▸ PIK3CD O00329 1/20 0.45
▸ PLK4 O00444 1/20 0.45
▸ STK25 O00506 1/20 0.45
▸ CIT O14578 1/20 0.45
▸ RIOK3 O14730 1/20 0.45
▸ CHEK1 O14757 1/20 0.45
▸ IKBKB O14920 1/20 0.45
▸ AURKA O14965 1/20 0.45
▸ GAK O14976 1/20 0.45
▸ CHUK O15111 1/20 0.45
▸ MUSK O15146 1/20 0.45
▸ EPHB6 O15197 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14213425 0.84 SYK (0.47) SYKADORA3TYRO3NTRK1NTRK3
SCHEMBL10239074 0.79 SYK (0.41) SYKADORA3TYRO3NTRK1NTRK3
SCHEMBL12654383 0.78 SYK (0.41) SYKADORA3TYRO3NTRK1NTRK3
SCHEMBL22096128 0.78 SYK (0.41) SYKADORA3TYRO3NTRK1NTRK3
SCHEMBL22192 0.78 SYK (0.41) SYKADORA3TYRO3NTRK1NTRK3
SCHEMBL24156807 0.78 SYK (0.41) SYKADORA3TYRO3NTRK1NTRK3
SCHEMBL12854262 0.77 SYK (0.69) SYKADORA3TYRO3NTRK1NTRK3
SCHEMBL16606964 0.76 SYK (0.52) SYKADORA3TYRO3NTRK1NTRK3
SCHEMBL23011877 0.76 SYK (0.51) SYKADORA3TYRO3NTRK1NTRK3
SCHEMBL5946341 0.75 SYK (0.39) SYKADORA3TYRO3NTRK1NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120309773-A1 HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS BIOCRYST PHARMACEUTICALS, INC. 2012-12-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309773-A1 HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS JAK2, JAK1, JAK3 SYK 85/4885ADORA3 4330/4885TYRO3 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback